Hidehito Horinouchi

5.7k citations
225 papers · 3.0k indexed · h-index 32

Hidehito Horinouchi

202 papers receiving 3.0k citations

Peers

Hidehito Horinouchi
Comparison fields: 5 of 108
  • Oncology 2.0k
  • Pulmonary and Respiratory Medicine 1.7k
  • Neurology 359
  • Cancer Research 309
  • Clinical Biochemistry 104
Replace C. Manegold with:
C. Manegold Germany
Takehito Shukuya Japan
Sergio Pedrazzoli Italy
Gavin Wright Australia
Cosimo Sperti Italy
Samir D. Undevia United States
Fumihiro Oshita Japan
Óscar Juan Spain
Susana Roselló Spain
Giuseppe Lo Russo Italy
Hidehito Horinouchi relative to C. Manegold Germany C. Manegold's profile →
Citations per field
00.5×10×12.5×
C. Manegold · 1×
Citations per year

Countries citing papers authored by Hidehito Horinouchi

Since Specialization
Citations

This map shows the geographic impact of Hidehito Horinouchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hidehito Horinouchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hidehito Horinouchi more than expected).

Fields of papers citing papers by Hidehito Horinouchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hidehito Horinouchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hidehito Horinouchi. The network helps show where Hidehito Horinouchi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Hidehito Horinouchi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hidehito Horinouchi Line = papers co-authored together Hidehito Horinouchi links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20241
3 20241
4 20244
5 20234
6 20234
7 20233
8 20231
9 20231
10 20232
11 202321
12 20226
13 20216
14 202118
15 202110
16 202015
17 202036
18 201810
19 20185
20 201858

About Hidehito Horinouchi

Hidehito Horinouchi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 225 papers that have together received 3.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (145 papers), Lung Cancer Research Studies (64 papers), Cancer Immunotherapy and Biomarkers (61 papers), Lung Cancer Diagnosis and Treatment (52 papers), Colorectal Cancer Treatments and Studies (38 papers), Neuroendocrine Tumor Research Advances (20 papers), Cancer Genomics and Diagnostics (19 papers) and HER2/EGFR in Cancer Research (14 papers). The work is most often cited by research in Oncology (2.0k citations), Pulmonary and Respiratory Medicine (1.7k citations) and Neurology (359 citations). Hidehito Horinouchi has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Yuichiro Ohe, Noboru Yamamoto, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Yasushi Goto, Tomohide Tamura, Koji Tsuta, Yuji Matsumoto and Shun‐ichi Watanabe. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026